Cargando…
Characterization of the effects of immunomodulatory drug fingolimod (FTY720) on human T cell receptor signaling pathways
Immune responses against gene therapy products limit its therapeutic efficacy and present a safety risk. Identification of agents that blunt immune reactions may aid in developing novel immunomodulatory therapies. Fingolimod (FTY720) is an FDA approved immunomodulatory drug for treating multiple scl...
Autores principales: | Baer, Alan, Colon-Moran, Winston, Bhattarai, Nirjal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053412/ https://www.ncbi.nlm.nih.gov/pubmed/30026610 http://dx.doi.org/10.1038/s41598-018-29355-0 |
Ejemplares similares
-
The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod
por: Patmanathan, Sathya Narayanan, et al.
Publicado: (2015) -
The emerging role of FTY720 (Fingolimod) in cancer treatment
por: White, Christopher, et al.
Publicado: (2016) -
Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011) -
Fingolimod (FTY720) Stimulates Ca(2+)/Calcineurin Signaling in Fission Yeast
por: Hagihara, Kanako, et al.
Publicado: (2013) -
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
por: Sharma, Sushil, et al.
Publicado: (2011)